NURO: NeuroMetrix Company Total Sales

NeuroMetrix, Inc. (NURO) management demonstrates pragmatism in device management and transparency in restructuring, despite stagnating revenue. The company's sales timeline displayed on GURU.Markets confirms this trend, where the value remains at 0.00. Growth relies on the Quell system and digital monitoring, while a lack of import dependence protects the business from geopolitical shocks.

NeuroMetrix Corp (NURO) - Company Sales from 07/04/2022 to 05/11/2025

Comprehensive metric breakdowns and analytics for neurometrix.com (NURO)

- market value and analyst target forecast:

Market Chart NeuroMetrix|NURO - Consensus Target

- market capitalization information:

Market Value NeuroMetrix Corp|NURO - Total Company Value

- book capitalization indicators:

Accounting Value of a Share NeuroMetrix|NURO - Company Net Assets|Market Capitalization to Book Value Ratio neurometrix.com|NURO - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

NURO - Company Net Income|Net Profit Forecast NeuroMetrix, Inc.|NURO - P/E Multiple|Projected Price to Earnings Ratio NeuroMetrix Corp|NURO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NeuroMetrix Corp|NURO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NeuroMetrix|NURO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months neurometrix.com|NURO - Earnings per share growth in current year|Expected earnings per share growth for next year NeuroMetrix, Inc.

- issuer revenue and sales details:

NURO - Revenue and Sales Volume|Company Expected Sales Volume NeuroMetrix|NURO - Market Cap to Revenue|Price to Expected Revenue Ratio NeuroMetrix Corp

Comprehensive company analysis:NeuroMetrix NURO

Portfolio managers are evaluating the operating model of NeuroMetrix, Inc. (NURO) through an analysis of daily revenue, which reveals the internal mechanics of cash inflows and flow stability. The sales momentum of NeuroMetrix, Inc. (NURO) confirms the commercial success of Quell wearable devices for neuropathic pain therapy, allowing investors to use the chart trajectory to identify the risk of capital freeze or confirm the fundamental strength of the issuer's market positions.

Competing companies